Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefano Bonora

Showing results (251-260 of 302) with videos related to

Pageof 31
Sort By:
Pharmaceuticals (Basel, Switzerland)|June 2, 2021
Development and Validation of an Up-to-Date Highly Sensitive UHPLC-MS/MS Method for the Simultaneous Quantification of Current Anti-HIV Nucleoside Analogues in Human PlasmaAmedeo De Nicolò, Alessandra Manca, Alice Ianniello, et al.
Open Heart|March 28, 2015
Cardiovascular disease in HIV patients: from bench to bedside and backwardsEnrico Cerrato, Andrea Calcagno, Fabrizio D'Ascenzo, et al.
Clinical Pharmacokinetics|August 2, 2020
Older Age is Associated with Higher Dolutegravir Exposure in Plasma and Cerebrospinal Fluid of People Living with HIVAndrea Calcagno, José Moltó, Alberto Borghetti, et al.
AIDS (London, England)|January 5, 2019
HIV-1 detection in the olfactory mucosa of HIV-1-infected participantsLuca Bertero, Sarah Beth Joseph, Mattia Trunfio, et al.
Pharmacogenetics and Genomics|January 11, 2011
Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphismMarco Siccardi, Antonio D'Avolio, Silvia Nozza, et al.
Antiviral Therapy|April 28, 2006
Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patientsAndrea Antinori, Maria Paola Trotta, Paola Nasta, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 9, 2024
Switching to Low Neurotoxic Antiretrovirals to Improve Neurocognition Among People Living With HIV-1-Associated Neurocognitive Disorder: The MARAND-X Randomized Clinical TrialAlessandro Lazzaro, Daniela Vai, Ambra Barco, et al.
The Journal of Antimicrobial Chemotherapy|February 3, 2016
Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIsStefanie Hennig, Elin M Svensson, Ronald Niebecker, et al.
HIV Research & Clinical Practice|March 5, 2020
96-week results of a dual therapy with darunavir/ritonavir plus rilpivirine once a day <i>vs</i> triple therapy in patients with suppressed viraemia: virological success and non-HIV related morbidity evaluationValentina Di Cristo, Fulvio Adorni, Renato Maserati, et al.
Antibiotics (Basel, Switzerland)|July 29, 2023
Real-Life Experience of Continuously Infused Ceftolozane/Tazobactam in Patients with Bronchiectasis and Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Infection in the Outpatient SettingFrancesco Venuti, Alberto Gaviraghi, Amedeo De Nicolò, et al.
Pageof 31

Showing results (251-260 of 302) with videos related to

Sort By:
Pageof 31
Pharmaceuticals (Basel, Switzerland)|June 2, 2021
Development and Validation of an Up-to-Date Highly Sensitive UHPLC-MS/MS Method for the Simultaneous Quantification of Current Anti-HIV Nucleoside Analogues in Human PlasmaAmedeo De Nicolò, Alessandra Manca, Alice Ianniello, et al.
Open Heart|March 28, 2015
Cardiovascular disease in HIV patients: from bench to bedside and backwardsEnrico Cerrato, Andrea Calcagno, Fabrizio D'Ascenzo, et al.
Clinical Pharmacokinetics|August 2, 2020
Older Age is Associated with Higher Dolutegravir Exposure in Plasma and Cerebrospinal Fluid of People Living with HIVAndrea Calcagno, José Moltó, Alberto Borghetti, et al.
AIDS (London, England)|January 5, 2019
HIV-1 detection in the olfactory mucosa of HIV-1-infected participantsLuca Bertero, Sarah Beth Joseph, Mattia Trunfio, et al.
Pharmacogenetics and Genomics|January 11, 2011
Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphismMarco Siccardi, Antonio D'Avolio, Silvia Nozza, et al.
Antiviral Therapy|April 28, 2006
Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patientsAndrea Antinori, Maria Paola Trotta, Paola Nasta, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 9, 2024
Switching to Low Neurotoxic Antiretrovirals to Improve Neurocognition Among People Living With HIV-1-Associated Neurocognitive Disorder: The MARAND-X Randomized Clinical TrialAlessandro Lazzaro, Daniela Vai, Ambra Barco, et al.
The Journal of Antimicrobial Chemotherapy|February 3, 2016
Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIsStefanie Hennig, Elin M Svensson, Ronald Niebecker, et al.
HIV Research & Clinical Practice|March 5, 2020
96-week results of a dual therapy with darunavir/ritonavir plus rilpivirine once a day <i>vs</i> triple therapy in patients with suppressed viraemia: virological success and non-HIV related morbidity evaluationValentina Di Cristo, Fulvio Adorni, Renato Maserati, et al.
Antibiotics (Basel, Switzerland)|July 29, 2023
Real-Life Experience of Continuously Infused Ceftolozane/Tazobactam in Patients with Bronchiectasis and Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Infection in the Outpatient SettingFrancesco Venuti, Alberto Gaviraghi, Amedeo De Nicolò, et al.
Pageof 31